The type 1 diabetes study sample
| . | Sample . |
|---|---|
| . | (N = 1,860) . |
| Sex | |
| Men, n (%) | 1,042 (56.0) |
| Women, n (%) | 818 (44.0) |
| Age, years | 48 (16) |
| Smoking status | |
| Never, n (%) | 1,285 (69.1) |
| Previous, n (%) | 336 (18.1) |
| Current, n (%) | 232 (12.5) |
| Diabetes | |
| Age at diagnosis, years | 23 (15) |
| Diabetes duration, years | 27 (15) |
| Multiple daily injections, n (%) | 1,438 (77.3) |
| Insulin pump, n (%) | 422 (22.7) |
| HbA1c, % | 7.8 (1.3) |
| HbA1c, mmol/mol | 62 (14) |
| Creatinine, µmol/L | 80 (40) |
| eGFR, mL/min/1.73 m2 | 83 (20) |
| Blood pressure | |
| Systolic, mmHg | 128 (15) |
| Diastolic, mmHg | 75 (9) |
| Lipids | |
| TGs, mmol/L | 0.8 (0.6–1.2) |
| Cholesterol, mmol/L | 4.7 (1.0) |
| HDL-C, mmol/L | 1.7 (0.5) |
| LDL-C, mmol/L | 2.5 (0.8) |
| Lp(a), nmol/L | 19 (10–72) |
| Additional treatment | |
| Platelet inhibition, n (%) | 291 (15.6) |
| Lipid lowering, n (%) | 741 (39.8) |
| Hypertension, n (%) | 758 (40.7) |
| Macrovascular complications | |
| CHD, n (%) | 128 (6.9) |
| CVL, n (%) | 63 (3.4) |
| Microvascular complications | |
| Albuminuria, n (%) | 255 (13.7) |
| Retinopathy, n (%) | 1,254 (67.4) |
| Neuropathy, n (%) | 390 (21.0) |
| Diabetic foot disease | |
| Ulceration, n (%) | 77 (4.1) |
| Calcified aortic valve disease | |
| Sclerosis/stenosis, n (%) | 88 (4.7) |
| . | Sample . |
|---|---|
| . | (N = 1,860) . |
| Sex | |
| Men, n (%) | 1,042 (56.0) |
| Women, n (%) | 818 (44.0) |
| Age, years | 48 (16) |
| Smoking status | |
| Never, n (%) | 1,285 (69.1) |
| Previous, n (%) | 336 (18.1) |
| Current, n (%) | 232 (12.5) |
| Diabetes | |
| Age at diagnosis, years | 23 (15) |
| Diabetes duration, years | 27 (15) |
| Multiple daily injections, n (%) | 1,438 (77.3) |
| Insulin pump, n (%) | 422 (22.7) |
| HbA1c, % | 7.8 (1.3) |
| HbA1c, mmol/mol | 62 (14) |
| Creatinine, µmol/L | 80 (40) |
| eGFR, mL/min/1.73 m2 | 83 (20) |
| Blood pressure | |
| Systolic, mmHg | 128 (15) |
| Diastolic, mmHg | 75 (9) |
| Lipids | |
| TGs, mmol/L | 0.8 (0.6–1.2) |
| Cholesterol, mmol/L | 4.7 (1.0) |
| HDL-C, mmol/L | 1.7 (0.5) |
| LDL-C, mmol/L | 2.5 (0.8) |
| Lp(a), nmol/L | 19 (10–72) |
| Additional treatment | |
| Platelet inhibition, n (%) | 291 (15.6) |
| Lipid lowering, n (%) | 741 (39.8) |
| Hypertension, n (%) | 758 (40.7) |
| Macrovascular complications | |
| CHD, n (%) | 128 (6.9) |
| CVL, n (%) | 63 (3.4) |
| Microvascular complications | |
| Albuminuria, n (%) | 255 (13.7) |
| Retinopathy, n (%) | 1,254 (67.4) |
| Neuropathy, n (%) | 390 (21.0) |
| Diabetic foot disease | |
| Ulceration, n (%) | 77 (4.1) |
| Calcified aortic valve disease | |
| Sclerosis/stenosis, n (%) | 88 (4.7) |
Data are presented as the mean (SD), the median (interquartile range), or as indicated otherwise. eGFR, estimated glomerular filtration rate.